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A Survey of the Use of Off-Label and Unlicensed Drugs in a Dutch
Children’s Hospital
Geert W. ’t Jong, MSc*; Arnold G. Vulto, PharmD§; Matthijs de Hoog, MD*;
Kirsten J. M. Schimmel, PharmD§; Dick Tibboel, MD, PhD‡; and John N. van den Anker, MD, PhD*¶
ABSTRACT. Background. The treatment of pediatric
patients with drugs in hospitals is being impeded by a
shortage in the availability of licensed drugs in an ap-
propriate formulation. We have studied the extent of use
of drugs that are not licensed for use in children (unli-
censed) and drugs that are used outside the terms of the
product license (off-label). We conducted this study in a
Dutch academic children’s hospital.
Methods. In a prospective study of 5 weeks’ duration,
we reviewed drug prescriptions in a pediatric ward and 3
intensive care units. We classified the prescribed drugs
in 3 main categories—licensed, unlicensed, and off-la-
bel—and determined the nature of their unlicensed and
off-label use.
Results. Two thousand one hundred thirty-nine
courses of drugs were administered to 237 patients in 442
patient-days. Of 2139 prescriptions, 725 (34%) were li-
censed, 1024 (48%) were unlicensed, and 390 (18%) were
off-label. In 392 (90%) of 435 patient-days, children re-
ceived 1 or more courses of an unlicensed or off-label
drug prescription in hospital.
Conclusion. With regard to the availability of drugs
of proven quality and adequate license for pediatric pa-
tients in hospital, dramatic shortcomings exist. As a re-
sult, drug legislation originally designed to protect pa-
tients and prescribing physicians against unsafe drug use
and unjustified claims has turned into an insurmount-
able threshold to make proper drugs available for a vul-
nerable minority of patients. Pediatrics 2001;108:1089–
1093; children, drug use, labeling, unlicensed, off-label,
licensing, drugs.
ABBREVIATIONS. MCU, medium care unit; NICU, neonatal in-
tensive care unit; SICU, surgical intensive care unit; PICU, pedi-
atric intensive care unit.
Many commercially available drugs are onlylicensed for use in adults and are not usedaccording to the product licensing in pedi-
atric practice. Furthermore, for many drugs, the
available formulations are unsuitable for pediatric
use,1 and for many compounds in common use in
pediatrics, preparations are not commercially avail-
able at all. There are several reasons for this situation.
According to the modern standards of drug evalua-
tion, obtaining a product license for a specific drug
for a specific indication in a specific patient group
necessitates extensive research. With children form-
ing only a minority in the drug market, the profit-
driven drug industry by nature is reluctant to invest
in pediatric drug studies. In addition, fear is growing
for unforeseen and hard-to-study long-term side ef-
fects. As a result, drug legislation originally designed
to protect patients and prescribing physicians
against unsafe drug use and unjustified claims has
turned into a barrier to making proper drugs avail-
able for a vulnerable minority of patients.
Other reasons are the ethical problem of research
in children, the reluctance of parents to allow their
children to participate in drug trials, and the techni-
cal challenges small study participants bring along.
Possibly because of the underestimation of the prob-
lem, there is lack of funding from government,
health care providers, and industry. As a result, pe-
diatric drug trials are relatively scarce and in many
cases, contain only a limited number of patients.
Consequently, most drugs used in clinical practice
in pediatrics are not licensed for children,2–6 and this
has lead to children being referred to as “therapeutic
orphans.”7 Use of these drugs is sometimes based on
the modification of adult formulations and dosage
strengths and extrapolation of doses used in adults.
This neglects the important differences between
adults and children in development and drug me-
tabolism and excretion.8 Often, dosage regimens are
based on clinical trials and published experience in
children, although not submitted to licensing scru-
tiny.
Surveys in the United Kingdom by Turner et al,
and by others,9–15 have shown that many drugs pre-
scribed to children in pediatric, and especially neo-
natal, care are not licensed for children, or are pre-
scribed “off-label” (ie, outside the terms of the
product license). With tightening rules in medical
practice and an increasing number of lawsuits, pedi-
atricians are in an unenviable position. In the United
States, about 80% of all drugs approved for the mar-
ket lack partial or complete information in the label
pertaining to use in pediatric patients.16–18 The US
Food and Drug Administration has implemented
new regulations to increase the number of drugs
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available for pediatric use.19,20 In Europe, similar
changes are under discussion, currently only with
very limited success.21,22
In contrast to many other European countries,
most Dutch hospital pharmacies provide their pedi-
atric wards with fully “homemade” pediatric formu-
lations or modified commercial preparations (eg,
strength-adapted suspensions, capsules) on a large
scale. We wanted to investigate the licensing status
of the drugs commonly used in a pediatric academic
setting against this background. We therefore stud-
ied in detail all drugs prescribed in 4 hospital units in
our academic children’s hospital.
METHODS
Setting
Data were retrieved from 4 hospital units of the Sophia Chil-
dren’s Hospital in Rotterdam, The Netherlands, an academic chil-
dren’s hospital. This highly specialized hospital provides the Rot-
terdam region with care for children that are seriously ill, and in
need of specific care. During a 5-week period (February to March
1999), we prospectively investigated 1 large, medium-care unit
and 3 intensive care units. These 4 hospital units were as follows:
medium care unit (MCU), 56 beds/cribs; neonatal intensive care
unit (NICU), 28 cribs; surgical intensive care unit (SICU), 18 beds/
cribs; and pediatric intensive care unit (PICU), 14 beds/cribs.
Design
To determine the drug licensing status of drugs prescribed to
children in this hospital, we prospectively gathered prescription
data study in a dynamic cohort. We studied all patients that were
hospitalized in 1 of the hospital units during the study period. We
defined each event in which the prescriptions of an individual
patient on a separate day have been investigated, as 1 “patient-
day.” Each hospital unit was studied for 1 day each week for 5
consecutive weeks, and was visited on a different day each week.
Data collection included: unit involved, week number, date of
birth, age, weight, gender, diagnosis or reason of admission, drugs
administered, form and route of administration, dose, frequency,
and indication for use. The use of the following drugs was not
recorded: standard intravenous crystalloid fluids, blood products,
total parental nutrition, and oxygen therapy.
Classification
All drugs administered were assessed for licensing status by
way of a classification system specially adapted to the Dutch
situation, although primarily based on a classification system
described and used in previous published studies in the United
Kingdom.10
In the main classification category, 4 main groups of prescrip-
tions were defined: 1) proprietary medications; 2) generic, or
nonproprietary medication; 3) commercial formulations modified
by the hospital pharmacy (modified); and 4) medications manu-
factured by the hospital pharmacy (home label).
A prescription was automatically defined unlicensed if “mod-
ified” or “home label” was applicable. In case of a modification,
the commercial manufacturer would not be liable for the altered
administered prescription, because the license of the original
product is not applicable to the modified product. In case of a
home-label drug, no license was applicable, because it was pro-
duced by the hospital pharmacy itself. These prescriptions were
not further classified for off-label use because the lack of proper
information texts.
If a prescription was a propriety or generic product, we further
classified for 5 other classification categories, namely age, dosage
form and route of administration, daily dosage used, number of
doses per day, and indication. If the prescription in 1 or more of
the other classification categories was not according to registra-
tion, it was defined “off-label.” Exceptions were made when the
prescription was “not licensed for use in children” or “contrain-
dicated for use in children” (contraindicated), or when doses for
use in children were not mentioned in the reference (no informa-
tion on use in children), in which case the prescription was de-
fined “unlicensed.”
The primary reference source used was the Repertorium 98/9923
(an official Dutch compendium with approved drug information
on drug specialties). The alternative source of information was the
Farmacotherapeutisch Kompas 9824 (a compendium provided by the
Dutch National Health Service), which was used if the drug in-
volved was not available as a proprietary medication, and there-
fore not mentioned in the Repertorium 98/99.
RESULTS
During the 5-week study period in February and
March 1999, 237 patients were included in the study
in a total of 448 patient-days. The ages of the patients
at admission ranged between 0 days and 17 years. Of
237 patients, 129 (54%) were male. The 4 hospital
units admitted 110 (MCU), 64 (NICU), 33 (SICU), and
31 (PICU) patients, receiving 905, 621, 308, and 305
prescriptions, respectively (Table 1). Fourteen pa-
tients switched from an intensive care unit to the
MCU during hospitalization. Most important rea-
sons for admission were: prematurity, bronchopul-
monary dysplasia, cardiac malformations, oncology,
cystic fibrosis, chronic renal failure, and asthmatics.
In 1414 (66%) of the 2 139 prescriptions, drugs
were either unlicensed (1024; 48%) or off-label (390;
18%). Three hundred ninety-two (90%) of all 435
patient-days contained unlicensed drugs or off-label
prescription. Of all prescriptions, 193 (9%) were com-
mercial formulations modified by the hospital phar-
macy (modified), and 567 (27%) were medications
manufactured by the hospital pharmacy (home la-
bel). This percentage was even higher in NICU.
Three hundred thirty-four (16%) drug prescriptions
were off-label for dose, and 100 (5%) were off-label
for age (Table 2).
A total of 189 drugs were prescribed, the most
frequently encountered drugs in the study were nys-
TABLE 1. Patient Characteristics
Hospital Unit MCU NICU SICU PICU Total
(Number of Beds/Cribs) (56) (28) (18) (14) (116)
Patients admitted 110 66 34 27 237
Gender
Male 64 33 14 18 129
Female 46 33 20 9 108
Age
Age range 4 d–17 y 0 d–6 mo 6 d–16 y 4 d–15 y 0 d–17 y
Median age 4.5 y 12 d 54 d 2.2 y 8.5 mo
Patient-days 186 130 70 49 435
Prescriptions 905 621 308 305 2139
Prescriptions per patient-day 4.9 4.8 4.4 6.2 4.9
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tatin, cisapride, and acetaminophen (Table 3). The
most frequently encountered unlicensed drugs and
off-label prescriptions in use were cisapride, caffeine,
and tobramycin (Table 4). Off-label use is mainly
attributable to use of different dose and frequency to
that recommended in the product license. Ipratro-
pium, budesonide, and salbutamol (Atrovent, Pulmi-
cort, and Ventolin) are used in various combinations
and dosage proportions. The components are dis-
solved in NaCl 0.9% by the hospital pharmacy, and
then used in an aerosol.
DISCUSSION
The licensing status of many of the drugs com-
monly used in our academic children’s hospital is
inadequate. Results show a high prevalence of unli-
censed (44%) and off-label (15%) drug use in our
MCU. We found even larger proportions of unli-
censed and off-label drug use in intensive care, and
especially in the NICU, as expected. Lack of flexible
pediatric formulations and lack of drugs properly
licensed for newborns and infants are important co-
factors. We found a strikingly high use of home-label
prescriptions in NICU (41%), which is mainly caused
by the lack of flexible pediatric formulations, which
the hospital pharmacy tries to overcome by manu-
facturing the needed formulations themselves.
We expected the number of drugs used (4.9 pre-
scriptions per patient day) in the MCU to be lower
than in the ICUs. However, no significant difference
is found. This is probably attributable to the rela-
tively high prevalence of chronic respiratory illness
(cystic fibrosis, asthma) in this patient population.
Studies in the United Kingdom by Choonara et
al11–14 showed similar results concerning the licens-
ing status of prescribed drugs. When comparing our
study to the UK studies, several aspects in design
have to be considered. The extensive use of medica-
tions modified by the hospital pharmacy (modified)
and formulations manufactured by the hospital
pharmacy (home label) in the Netherlands compared
with the studies performed in the United Kingdom
results in very high percentages of unlicensed drug
prescription. The difference between these studies is
attributable to the pharmacy strategy to dedicate
resources to clinical pharmacy service provision
rather than manufacturing, which is followed by
most departments in the United Kingdom. UK phar-
macists are allowed to extemporaneously dispense
any drug for an individual patient, but good manu-
facturing practice regulations must rightly be fol-
lowed if done on a larger scale. In the Netherlands,
hospitals pharmacies often manufacture on a large
scale for cost-saving reasons. Besides that, the num-
ber of drugs licensed for use in the Netherlands is
smaller, also resulting in a higher proportion of mod-
ified medications and home label formulations; they
together make up for 36% of all prescriptions. The
method of data collection differed not only in length
of study period, but also in data collection interval.
In an international study in pediatric wards that we
participated in,25 we used some of the data from this
study. Preliminary results of this study have been
reported in abbreviated form.26 The classification
system used in these preliminary results was slightly
different, but to facilitate comparison we adapted
TABLE 3. The 5 Most Frequently Prescribed Drugs in 4 Different Hospital Units During the 5-Week Investigation Period
MCU %* NICU % SICU % PICU % Total %
Acetaminophen 4 Caffeine 11 Nystatin 17 Amphotericin B 9 Nystatin 5
Amphotericin B 3 Nystatin 9 Cisapride 8 Cisapride 7 Cisapride 4
Ondansetron 3 Vitamin D3 and E 7 Acetaminophen 5 Acetaminophen 6 Acetaminophen 4
Furosemide 2 Ipratropium and salbutamol 5 Cefotaxime 5 Cotrimoxazole 6 Caffeine 4
Spironolactone 2 Tobramycin 5 Furosemide 4 Furosemide 6 Furosemide 3
* % indicates the percentage of all drug prescriptions in the hospital unit.











Licensed 375 (41%) 153 (24%) 100 (32%) 97 (32%) 725 (34%)
Unlicensed Contraindicated 9 (1%) 5 (1%) 7 (2%) 1 (1%) 22 (1%)
No information on use in children 112 (12%) 46 (7%) 33 (11%) 51 (17%) 242 (11%)
Prescriptions manufactured or modified
by the hospital pharmacy 239 (26%) 333 (54%) 80 (26%) 108 (35%) 760 (36%)
Total unlicensed 360 (40%) 384 (62%) 120 (39%) 160 (52%) 1024 (48%)
Off-label Dose 53 (6%) 11 (2%) 21 (7%) 17 (6%) 102 (5%)
Dose and frequency 50 (6%) 7 (1%) 8 (3%) 20 (7%) 85 (4%)
Dose and indication 15 (2%) 1 (1%) 1 (1%) 17 (1%)
Dose, frequency, and indication 4 (1%) 3 (1%) 13 (4%) 20 (1%)
Dose, frequency, and route 2 (1%) 14 (2%) 1 (1%) 17 (1%)
Dose, frequency, and age 33 (4%) 19 (3%) 37 (12%) 1 (1%) 90 (4%)
Dose, frequency, age, and route 1 (1%) 2 (1%) 3 (1%)
Age 4 (1%) 1 (1%) 2 (1%) 7 (1%)
Frequency 4 (1%) 29 (5%) 6 (2%) 2 (1%) 41 (2%)
Indication 2 (1%) 1 (1%) 1 (1%) 2 (1%) 6 (1%)
Route of administration 2 (1%) 2 (1%)
Total off-label 170 (19%) 84 (14%) 88 (29%) 48 (16%) 390 (18%)
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our data to the classification system used in the
surveys by Turner et al.10
It is important to recognize that off-label or unli-
censed use of a drug may not be an inappropriate use
(because of reasonable research based foundations of
prescription protocol), but may be judged as such
when the legal liability of the physician would be
questioned in court, because the prescription is not in
accordance with labeling information. In our pediat-
ric wards, most drug use is based either on long-
standing experience or evidence obtained from the
literature. The majority of drugs are prescribed
within established protocols. However, the same
standards of efficacy and safety cannot be applied as
for the adult population. Drugs that were prescribed
while contraindicated or unlicensed for age may be
particularly unsafe, considering the lack of research
completed on these drugs, and the potency of these
drugs. They included vigabatrin (unlicensed in chil-
dren 10 kg) and ciprofloxacin (contraindicated).
Results give a good impression of the extent of
unlicensed and off-label drug prescription in very
specialized pediatric care in the Netherlands. In gen-
eral hospital pediatric care, and care provided to
children by general practitioners, hardly any infor-
mation is available on the extent of unlicensed and
off-label drug prescription. We hope that future re-
search in these areas will provide us of better knowl-
edge of the extent of this problem.
We strongly support the Food and Drug Admin-
istration’s Pediatric Rule.19 Despite various gaps in
these regulations, they are very important for the
accomplishment of equality in safety and efficacy of
pharmaceutical products in adults and children.27,28
The extension of prescribing information of already
licensed products with pediatric data are a matter of
public interest and therefore should be solved be-
tween the industry and the medical community with
public support. In return for public support, the li-
cense holder should be willing to develop flexible
pediatric formulations (like droplets, suspensions,
linctus, different strengths, capsules, etc). Older
drugs that do not have a patent are however ex-
cluded from this rule, despite the fact that they are
frequently used. A more difficult problem is to make
currently unavailable preparations in need, more
generally available. In most countries, according to
good manufacturing practice regulations hospital
pharmacies are not able to manufacture drugs on a
larger scale than facilitation of its hospital(s) re-
quires. It is of crucial importance to investigate
whether manufacturers of generic drug products are
able to produce certain products on a continent-wide
scale (Europe, United States), provided that the in-
ternational pediatric community would be able to
standardize their practices to make this effort eco-
nomically reasonable. International collaboration
could be realized and coordinated through organiza-
tions like the European Network for Drug Investiga-
tion in Children,29 the American Society for Clinical
Pharmacology and Therapeutics, the European Soci-
ety for Clinical Pharmacology, and the Neonatal and
Pediatric Pharmacists Group in the United Kingdom.
We hope that drug regulation authorities would sup-
port this movement by facilitating an orphan status
of such products, thereby reducing the investment
risk of the producer. Accumulation of pediatric drug
data could be an important strategy, given that effi-
cacy and safety information becomes available be-
yond reasonable doubt and without very high finan-
cial risks for the license holder.
Although drug regulations in general are intended
for protection of patients and prescribing physicians,
society should be willing to pay the price when side
effects of such regulations become counterproduc-
tive and unacceptable for children who constitute the
future of the society. We have an obligation to inves-
tigate seriously every possibility to reverse this
highly unfortunate situation in which the progress of
medical care is not available for the most vulnerable
and defenseless among us.
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STUDY TO DEVELOP WAY TO MONITOR CANCER CARE
Responding to a call to improve the quality of cancer care in the United States,
a leading cancer organization said that it was working with other groups to
develop a national system to monitor how well each cancer patient is treated.
. . . The ultimate goal is to develop specific measures of quality spanning the
entire course of care, from diagnosis to cure or death. Such measures could then be
used to hold health care providers accountable for the quality of cancer care.
. . . “There is no national cancer care program or system of care in the United
States,” the report said. It also said that the government had numerous cancer
programs and research, “but in no one place are these disparate efforts coordinated
or even described.”
A substantial, but unmeasured, number of cancer patients do not receive care
known to be effective for their condition, the medical institute said, and the reasons
for failure to deliver high-quality care could come from overuse, underuse, or
misuse of proper therapy but have not been studied adequately.
Conducting clinical trials to determine the safety and effectiveness of therapies
is a first step in assessing quality. But too few patients participate in such trials even
though studies show that routine care costs in cancer clinical trials are no more
than in standard care, cancer experts have said.
Altman LK. New York Times. May 21, 2000
Noted by JFL, MD
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